Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

10.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.2K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoxygenase (LOX) signaling in epilepsy: Pathophysiology and therapeutic prospects.

Neurobiology of disease·2026
Same author

QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models.

Molecular cancer therapeutics·2026
Same author

Novel EP2 Antagonist Attenuates Microgliosis and Memory Deficits in Pilocarpine-Induced Status Epilepticus Mice.

Journal of medicinal chemistry·2026
Same author

Topical difamilast for the treatment of mild-to-moderate atopic dermatitis.

Trends in pharmacological sciences·2026
Same author

Development of highly potent EP2 antagonists as novel anti-inflammatory neuroprotectants.

Bioorganic & medicinal chemistry·2026
Same author

Zycubo (copper histidinate), the first treatment for pediatric Menkes disease.

Trends in pharmacological sciences·2026

Related Experiment Video

Updated: Apr 28, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

16.2K

Development of second generation EP2 antagonists with high selectivity.

Thota Ganesh1, Jianxiong Jiang1, Ray Dingledine1

  • 1Department of Pharmacology, School of Medicine, Emory University, 1510 Clifton Rd, Atlanta, GA 30322, USA.

European Journal of Medicinal Chemistry
|June 18, 2014
PubMed
Summary

Researchers developed new EP2 receptor antagonists, improving anti-inflammatory therapy. These compounds offer high potency and selectivity, potentially avoiding side effects associated with older treatments.

Keywords:
Anti-inflammatoryCyclic AMPG protein-coupled receptorIndole-amidesTR-FRET assay

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

2.6K

Related Experiment Videos

Last Updated: Apr 28, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

16.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

2.6K

Area of Science:

  • Pharmacology and Medicinal Chemistry
  • Immunology
  • Neuroscience

Background:

  • The EP2 receptor plays a role in exacerbating various central nervous system (CNS) and peripheral diseases.
  • EP2 receptor deletion in mice mimics COX-2 inhibition effects, suggesting a novel anti-inflammatory therapeutic strategy.
  • Previous EP2 antagonists had moderate selectivity and contained an acrylamide moiety, raising concerns about potential liver toxicity.

Purpose of the Study:

  • To develop a second-generation EP2 receptor antagonist.
  • To improve selectivity against other prostanoid receptors.
  • To eliminate the acrylamide functionality to mitigate potential liver toxicity.

Main Methods:

  • Design and synthesis of novel cinnamic amide derivatives.
  • In vitro assays to determine EP2 receptor antagonist potency.
  • Selectivity profiling against a panel of prostanoid receptors (DP1, DP2, EP1, EP3, EP4).
  • Assessment of structural modifications to remove the acrylamide moiety.

Main Results:

  • The new compounds are potent EP2 receptor antagonists.
  • Achieved significantly improved selectivity (>1000-fold) for EP2 over other prostanoid receptors.
  • The developed compounds lack the potentially hepatotoxic acrylamide functionality.

Conclusions:

  • Second-generation EP2 antagonists demonstrate high potency and excellent selectivity.
  • These novel compounds represent a promising advancement for anti-inflammatory therapies targeting EP2.
  • The absence of the acrylamide moiety may lead to a safer profile for chronic use.